Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566. A Phase 1, Open-Label, Dose Escalation Study of PF-04518600 as a Single Agent and in Combination
With PF-05082566 in Patients With Selected Locally Advanced or Metastatic Cancers.